Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Short Interest Update

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) was the recipient of a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,804,605 shares, a decline of 72.7% from the April 30th total of 6,612,971 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average trading volume of 1,881,607 shares, the short-interest ratio is presently 1.0 days.

Curaleaf Stock Up 0.9%

Shares of Curaleaf stock traded up $0.03 during trading on Friday, hitting $3.59. 524,926 shares of the stock traded hands, compared to its average volume of 1,081,231. The stock has a market cap of $2.51 billion, a P/E ratio of -27.63 and a beta of 1.58. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.74 and a current ratio of 1.56. Curaleaf has a twelve month low of $0.72 and a twelve month high of $5.05. The company has a fifty day moving average price of $2.95 and a two-hundred day moving average price of $2.68.

Curaleaf shares are going to reverse split on the morning of Friday, June 5th. The 1-3 reverse split was announced on Tuesday, May 26th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, June 4th.

Curaleaf (OTCMKTS:CURLF) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.17. The business had revenue of $324.23 million during the quarter, compared to analyst estimates of $316.62 million. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%. Equities research analysts predict that Curaleaf will post -0.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Zacks Research raised Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat.com, Curaleaf has a consensus rating of “Strong Buy”.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.